SMARTCOUGH-C is a study that will evaluate the efficacy of the ResAppDx software application in the diagnosis of childhood pneumonia and other respiratory conditions from cough sounds.
ResApp’s smartphone app works by using algorithms to analyse the sound of a patient’s cough and providing a diagnosis.
The primary endpoint for the new study will be the diagnosis of pneumonia with the secondary endpoints being diagnosis of other common childhood respiratory diseases.
This includes upper respiratory tract infection, croup, bronchiolitis and asthma.
Currently, respiratory disease diagnosis is based on a combination of auscultation, imaging and laboratory tests.
An instant, accurate diagnostic test delivered via smartphones could greatly improve patient management, give greater access to healthcare and reduce costs.
Worldwide, pneumonia is the leading cause of death of children under five years of age and is the most common reason for U.S. children to be hospitalised.
ResApp completed an oversubscribed $12.5 million capital raising in April 2016 at $0.02 per share, finding support from new and existing institutional and sophisticated investors.
For investors that participated in the raising, it has been a profitable exercise to date, with the share price more than doubling since April to $0.45.
ResApp is well funded with $13 million in cash as at 30 September 2016.